Carbohydrate Antigen 19-9 (CA19-9) Antikörper

Antigen: Carbohydrate Antigen 19-9 (CA19-9)

Klonalität: Monoklonal (C241:5:1:4)

Wirt: Maus

Reaktivität: Human

Applikation: Immunhistochemie (Paraffinschnitte) (IHC (p))

Produktnummer: ABIN95812

Produktbeschreibung

Weitere Bezeichnung: CA 19-9

Immunogen: Human colorectal adenocarcinoma cell line COLO 205.

Format: Ig-fraction

Isotyp: IgG1

Klon: C241:5:1:4

Spezifität: This antibody reacts specifically with Sialyl Lewisa and recognizes an epitope being designated CA 19-9. It does not cross reacts with Lewisa and Lewisb. CA 19-9 has been shown to be useful marker in the diagnosis and management of gastrointestinal cancers.

Anwendungen

Applikationshinweise: Titer/Working Dilution: This antibody may be diluted to a titer of 1:25-1:50 in an ABC method. However, depending on the staining conditions employed, we suggest that final dilution should be determined by the user. Staining Protocol: We suggest an incubation period of 30 minutes at room temperature. However, depending upon the fixation conditions and the staining system employed, optimal incubation should be determined by the user. Formalin fixed paraffin embedded tissue sections require high temperature antigen unmasking with 10 mM citrate buffer, pH 6.0 prior to immunostaining. Positive Control: Colon carcinoma. Cellular localization: Cytoplasmic

Konzentration: 100ug/ml approximately

Buffer: This antibody is supplied as tissue culture supernatant containing sodium azide as preservative.

Lagerung: Store the antibody at 2-8o c. Do not use it beyond the expiration date stated on the label.

Forschungsgebiet: Krebs

Beschränkungen: Für Forschungszwecke. Als CE-zertifizierter Antikörper in der Europäischen Union für In Vitro Diagnostik (IVD) zugelassen.

Publikationen

Publikationen: Johansson, Nilsson, Baeckstroem et al.: "Novel epitopes on the CA50-carrying antigen: chemical and immunochemical studies." in: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, Vol. 12, Issue 3, pp. 159-70, 1991 (PubMed).

Kuusela, Haglund, Roberts: "Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases." in: British journal of cancer, Vol. 63, Issue 4, pp. 636-40, 1991 (PubMed).

Haglund, Lindgren, Roberts et al.: "Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9." in: British journal of cancer, Vol. 60, Issue 6, pp. 845-51, 1990 (PubMed).